Delcath Systems (DCTH) 10-Q 8 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 07, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	0000872912
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	001-16133
Entity Tax Identification Number	061245881
Entity Address, Address Line One	1633 Broadway
Entity Address, Address Line Two	Suite 22C
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	212
Local Phone Number	489-2100
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		18,277,807
Document Fiscal Year Focus	2019
Trading Symbol	DCTH
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents		$ 352	$ 2,516
Restricted cash		1,062	1,062
Accounts receivables, net		180	585
Inventories		687	858
Prepaid expenses and other current assets		664	898
Total current assets		2,945	5,919
Property, plant and equipment, net		805	925
Right-of-use assets		1,886
Total assets		5,636	6,844
Current liabilities
Accounts payable		10,713	7,715
Accrued expenses		9,119	7,964
Notes payable, net of debt discount		9,838
Convertible notes payable, net of debt discount		523	2,038
Lease liabilities, current portion		1,050
Warrant liability		9	33
Total current liabilities		31,252	17,750
Deferred revenue		3,143	3,405
Lease liabilities, long-term portion		848
Other non-current liabilities		122	628
Total liabilities		35,365	21,783
Commitments and contingencies
Stockholders' deficit
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares and 101 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively		0	0
Common stock, $.01 par value; 1,000,000,000 shares authorized; 18,277,807 and 10,299,954 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively*	[1]	183	103
Additional paid-in capital		328,018	328,962
Accumulated deficit		(357,907)	(344,054)
Accumulated other comprehensive income		(23)	50
Total stockholders' deficit		(29,729)	(14,939)
Total liabilities and stockholders' deficit		$ 5,636	$ 6,844
[1]	reflects a one-for-five hundred (1:500) reverse stock split effected on May 2, 2018.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	101
Preferred stock, shares outstanding (in shares)	0	101
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	18,277,807	10,299,954
Common stock, shares outstanding (in shares)	18,277,807	10,299,954

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Cost of goods sold		$ (172)	$ (220)	$ (268)	$ (367)
Gross profit		240	638	414	1,193
Operating expenses:
Selling, general and administrative		2,653	2,641	5,203	5,007
Research and development		1,714	4,089	5,011	9,781
Total operating expenses		4,367	6,730	10,214	14,788
Operating loss		(4,127)	(6,092)	(9,800)	(13,595)
Change in fair value of the warrant liability, net		10	2,513	17	17,209
Loss on issuance of financial instrument		(6)	(2,826)	(6)	(2,826)
Interest expense		(1,837)	(248)	(4,064)	(251)
Other income (expense)		1	(5)		(10)
Net (loss) income		(5,959)	(6,658)	(13,853)	527
Other comprehensive (loss) income:
Foreign currency translation adjustments		(23)	(36)	(74)	(78)
Other comprehensive (loss) income		$ (5,982)	$ (6,694)	$ (13,927)	$ 449
Common share data:
Basic (loss) income per common share	[1]	$ (0.08)	$ (7.26)	$ (0.19)	$ 0.67
Diluted loss per common share	[1]	$ (0.08)	$ (7.26)	$ (0.19)	$ (0.12)
Weighted average number of basic shares outstanding	[1]	71,303,364	916,706	72,069,390	788,512
Weighted average number of diluted shares outstanding	[1]	71,303,364	916,706	72,069,390	799,430
Product Revenue [Member]
Revenue		$ 221	$ 858	$ 311	$ 1,560
Other Revenue [Member]
Revenue		$ 191		$ 371
[1]	reflects a one-for-five hundred (1:500) reverse stock split effected on May 2, 2018.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)	May 02, 2018
Income Statement [Abstract]
Reverse stock split	1:500
Reverse stock split ratio	0.002

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Series D Warrants [Member]	Series D Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]Series D Warrants [Member]	Preferred Stock [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Treasury Stock [Member]	Additional Paid in Capital [Member]	Additional Paid in Capital [Member]Series D Warrants [Member]	Additional Paid in Capital [Member]Series D Preferred Stock [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2017	$ 678			$ 3				$ (51)	$ 325,516			$ (324,832)	$ 42
Balance (in shares) at Dec. 31, 2017				263,305				(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	7								7
Compensation expense for issuance of restricted stock	14								14
Sale of common stock, net of expenses	4,251			$ 6					4,245
Sale of common stock, net of expenses (in shares)				668,854
Fair value of warrants issued	(18,306)								(18,306)
Net (loss) income	7,185											7,185
Total comprehensive loss	(34)												(34)
Balance at Mar. 31, 2018	(6,205)			$ 9				$ (51)	311,476			(317,647)	8
Balance (in shares) at Mar. 31, 2018				932,159				(1)
Balance at Dec. 31, 2017	678			$ 3				$ (51)	325,516			(324,832)	42
Balance (in shares) at Dec. 31, 2017				263,305				(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	527
Balance at Jun. 30, 2018	(13,090)			$ 9				$ (51)	311,293			(324,305)	(36)
Balance (in shares) at Jun. 30, 2018				932,159				(1)
Balance at Mar. 31, 2018	(6,205)			$ 9				$ (51)	311,476			(317,647)	8
Balance (in shares) at Mar. 31, 2018				932,159				(1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	(47)								(47)
Compensation expense for issuance of restricted stock	(95)								(95)
Sale of common stock, net of expenses	(41)								(41)
Net (loss) income	(6,658)											(6,658)
Total comprehensive loss	(44)												(44)
Balance at Jun. 30, 2018	(13,090)			$ 9				$ (51)	311,293			(324,305)	(36)
Balance (in shares) at Jun. 30, 2018				932,159				(1)
Balance at Dec. 31, 2018	(14,939)			$ 103					328,962			(344,054)	50
Balance (in shares) at Dec. 31, 2018				10,299,954		101
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	54								54
Compensation expense for issuance of restricted stock	4								4
Compensation expense for issuance of restricted stock (in shares)				15,000
Issuance of Series D Preferred Stock			$ 150								$ 150
Issuance of Series D Preferred Stock (in shares)							15
Retirement of Series D Preferred Stock	(1,160)								(1,160)
Retirement of Series D Preferred Stock (in Shares)						(116)
Exercise of Pre-Funded Series D Warrants					$ 41					$ (41)
Exercise of pre-funded Series D Warrants (in shares)					4,119,500
Net (loss) income	(7,894)											(7,894)
Total comprehensive loss	7												7
Balance at Mar. 31, 2019	(23,778)			$ 144					327,969			(351,948)	57
Balance (in shares) at Mar. 31, 2019				14,434,454
Balance at Dec. 31, 2018	$ (14,939)			$ 103					328,962			(344,054)	50
Balance (in shares) at Dec. 31, 2018				10,299,954		101
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exchange of warrants (in shares)	64,000
Net (loss) income	$ (13,853)
Balance at Jun. 30, 2019	(29,729)			$ 183					328,018			(357,907)	(23)
Balance (in shares) at Jun. 30, 2019				18,277,807
Balance at Mar. 31, 2019	(23,778)			$ 144					327,969			(351,948)	57
Balance (in shares) at Mar. 31, 2019				14,434,454
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	75								75
Exercise of Pre-Funded Series D Warrants		$ (1)			$ 38					$ (39)
Exercise of pre-funded Series D Warrants (in shares)					3,779,353
Exchange of warrants	14			$ 1					13
Exchange of warrants (in shares)				64,000
Net (loss) income	(5,959)											(5,959)
Total comprehensive loss	(80)												(80)
Balance at Jun. 30, 2019	$ (29,729)			$ 183					$ 328,018			$ (357,907)	$ (23)
Balance (in shares) at Jun. 30, 2019				18,277,807

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net (loss) income	$ (13,853)	$ 527
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	129	(40)
Restricted stock compensation expense	4	(81)
Depreciation expense	122	236
Amortization of right of use assets	552	0
Warrant liability fair value adjustment	(17)	(17,209)
Non-cash interest income	0	(1)
Loss on issuance of financial instrument	6	2,826
Interest expense accrued related to convertible notes	329	0
Debt discount amortization	3,444	238
Changes in assets and liabilities:
Prepaid expenses and other assets	232	318
Accounts receivable	404	(163)
Inventories	143	43
Accounts payable and accrued expenses	3,827	3,985
Deferred revenue	(240)	0
Other non-current liabilities	(504)	44
Principal payments on leases	(540)	0
Net cash used in operating activities	(5,962)	(9,277)
Cash flows from investing activities:
Purchase of property, plant and equipment	(2)	(39)
Net cash used in investing activities	(2)	(39)
Cash flows from financing activities:
Net proceeds from the issuance of debt	3,719	0
Net proceeds from sale of common stock and warrants	0	4,210
Net proceeds from convertible debt financing	0	2,172
Net cash provided by financing activities	3,869	6,382
Foreign currency effects on cash, cash equivalents and restricted cash	(69)	(45)
Net decrease in cash, cash equivalents and restricted cash	(2,164)	(2,979)
Cash, cash equivalents and restricted cash:
Beginning of period	3,578	5,324
End of period	1,414	2,345
Supplemental non-cash financing activities:
Fair value of warrants issued	0	23,532
Series D Preferred Stock [Member]
Cash flows from financing activities:
Net proceeds from sale of Series D Preferred Stock	$ 150	$ 0

General

General	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General	(1) General The unaudited interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three and six months ended June 30, 2019 and 2018 should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “Annual Report”), which was filed with the Securities Exchange Commission (the “SEC”) on June 14, 2019 and may also be found on the Company’s website (www.delcath.com). In these notes to the condensed consolidated financial statements the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries. Description of Business Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (“Melphalan/HDS”) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is commercially available under the trade name Delcath Hepatic CHEMOSAT ® Delivery System for Melphalan (“CHEMOSAT”), where it has been used at major medical centers to treat a wide range of cancers of the liver. Our primary research focus is on ocular melanoma liver metastases (“mOM”) and intrahepatic cholangiocarcinoma (“ICC”), a type of primary liver cancer, and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need. Our clinical development program (“CDP”) for Melphalan/HDS is comprised of The FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the “FOCUS Trial”), a global registration clinical trial that is investigating objective response rate in mOM, and the ALIGN Trial, a global Phase 3 clinical trial for ICC (the “ALIGN Trial”). Our CDP also includes a registry for CHEMOSAT commercial cases performed in Europe and sponsorship of select investigator-initiated trials (“IITs”). Liquidity and Operating Matters The accompanying interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and expects to continue incurring losses for the next several years. These losses, among other factors, raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern. Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended June 30, 2019 and 2018; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period. Significant Accounting Policies A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies Recently Adopted Accounting Pronouncements In February 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220). ASU 2018-02 allows a company to elect a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. ASU 2018-02 is effective for periods beginning after December 15, 2018. Upon adoption of ASU 2018-02, the Company did not elect to reclassify the tax effects of the Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings, as the stranded tax effects were insignificant. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) effective January 1, 2019, electing the practical expedients and applying the transition provisions as of the effective date. Reporting periods beginning on or after January 1, 2019 are presented under Topic 842, while prior period amounts, as reported under previous GAAP, were not adjusted. The adoption of Topic 842 on January 1, 2019 did not have a significant impact on the Company’s consolidated results of operations or cash flows.

Restricted Cash

Restricted Cash	6 Months Ended
	Jun. 30, 2019
Restricted Cash [Abstract]
Restricted Cash	(2) Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in Restricted Cash Cash, cash equivalents, and r estricted cash balances were as follows: June 30, December 31, (in thousands) 2019 2018 Cash and cash equivalents $ 352 $ 2,516 Letters of credit 1,012 1,012 Security for credit cards 50 50 Total cash, cash equivalents and restricted cash shown in the statements of cash flows $ 1,414 $ 3,578

Inventories

Inventories	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	(3) Inventories Inventories consist of the following: June 30, December 31, (in thousands) 2019 2018 Raw materials $ 307 $ 358 Work-in-process 380 500 Total inventories $ 687 $ 858

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses And Other Current Assets	(4) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: June 30, December 31, (in thousands) 2019 2018 Insurance premiums $ 175 $ 140 Sublease income 127 — Financing costs 80 — Security deposit 50 51 Income tax and VAT receivable 31 579 Other 1 201 128 Total prepaid expenses and other current assets $ 664 $ 898 1 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at June 30, 2019 and December 31, 2018.

Property, Plant, and Equipment

Property, Plant, and Equipment	6 Months Ended
	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Property, Plant, and Equipment	(5) Property, Plant, and Equipment Property, plant, and equipment consist of the following: June 30, December 31, Estimated (in thousands) 2019 2018 Useful Life Buildings and land $ 589 $ 589 30 years - Buildings Enterprise hardware and software 1,742 1,742 3 years Leaseholds 1,700 1,701 Lesser of lease term or estimated useful life Equipment 1,003 1,002 7 years Furniture 198 198 5 years Property, plant and equipment, gross 5,232 5,232 Accumulated depreciation (4,427 ) (4,307 ) Property, plant and equipment, net $ 805 $ 925 Depreciation expense for the three and six months ended June 30, 2019 was approximately $0.1 million and $0.1 million, respectively as compared to approximately $0.1 million and $0.2 million, respectively, for the same periods in 2018.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Accrued Expenses	(6) Accrued Expenses Accrued expenses consist of the following: June 30, December 31, (in thousands) 2019 2018 Compensation, excluding taxes $ 3,469 $ 1,785 Clinical trial expenses 4,289 4,530 Interest payable 731 402 Other 1 630 1,247 Total accrued expenses $ 9,119 $ 7,964 1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at June 30, 2019 and December 31, 2018.

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	(7) Leases The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating and financing leases. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. The following table summarizes the Company’s operating and financing leases as of and for the six months ended June 30, 2019: (in thousands) U.S. Ireland Total Lease cost Operating lease cost $ 475 $ 112 $ 587 Financing lease cost 19 — 19 Sublease income (215 ) (93 ) (308 ) Total $ 279 $ 19 298 Other information Operating cash flows out from operating leases (516 ) (112 ) (628 ) Operating cash flows in from operating leases 215 93 308 Operating cash flows from financing leases (24 ) — (24 ) Right-of-use assets exchanged for new operating lease liabilities 874 — 874 Weighted average remaining lease term 1.7 2.1 Weighted average discount rate - operating leases 8 % 8 % Maturities of the Company’s operating leases, excluding short-term leases, are as follows: (in thousands) U.S. Ireland Total Six months ended December 31, 2019 $ 472 $ 107 $ 579 Year ended December 31, 2020 936 213 1,149 Year ended December 31, 2021 190 124 314 Total 1,598 444 2,042 Less present value discount (108 ) (36 ) (144 ) Operating lease liabilities included in the condensed consolidated balance sheets at June 30, 2019 $ 1,490 $ 408 $ 1,898

Outstanding Debt

Outstanding Debt	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Outstanding Debt	(8) Outstanding Debt On April 19, 2019, April 26, 2019, May 9, 2019 and May 23, 2019, the Company issued 8% senior secured notes (collectively, the “2019 Notes”) in the aggregate principal amount of $3.3 million, to two institutional investors. The 2019 Notes bore interest at the rate of 8% per annum and were to mature on the six month anniversary of issuance in each case. The 2019 Notes were not convertible. The 2019 Notes contained standard events of default and remedies and are secured by a lien on the Company’s assets. The 2019 Notes were exchanged as part of the recent equity financing discussed further in Note 14 and are no longer outstanding. In March 2019, the Company exchanged all issued and outstanding shares of its Series D Preferred Stock (having an aggregate stated value of $1,160,000) and received $400,000 in cash proceeds in exchange for a senior secured promissory note (the “March 2019 Note”) in the principal amount of $1,560,000. The March 2019 Note bore interest at the rate of 8% per annum, and were to mature on April 1, 2020, and was not convertible. The principal is recognized in notes payable on the Condensed Consolidated Balance Sheet. The March 2019 Note was exchanged as part of the recent equity financing discussed further in Note 14 and is no longer outstanding. On June 4, 2018, July 21, 2018, August 29, 2018, and September 21, 2018, the Company issued 8% senior secured convertible notes (collectively, “the 2018 Notes”) in the aggregate principal amount of $9.4 million to several institutional investors. The 2018 Notes bore interest at the rate of 8% per annum and had maturity dates between December 2018 and March 2021. T he 2018 Notes were initially convertible and secured pursuant to a Security Agreement which created a first priority security interest in all of the personal property (other than Excluded Collateral as defined in the Security Agreement) of the Company of every kind and description, tangible or intangible, whether currently owned and existing or created or acquired in the future. The following tables provide a summary of the various notes issued at June 30, 2019 and December 31, 2018: (in millions) Conversion price Current interest rate Principal Unamortized discount Carrying value Short term convertible notes payable 8.0% 2018 Notes $ 1.75 18 % $ 0.6 (0.1 ) $ 0.5 Short term notes payable 8.0% 2018 Notes — 18 % 5.0 (0.1 ) 4.9 8.0% 2019 Notes — 8 % 4.9 — 4.9 9.9 (0.1 ) 9.8 Balance at June 30, 2019 $ 10.5 $ (0.2 ) $ 10.3 (in millions) Interest rate Conversion price Principal Unamortized discount Carrying value December 4, 2018 8.0% $ 1.75 $ 1.7 $ — $ 1.7 March 1, 2019 8.0% $ 1.75 0.6 (0.5 ) 0.1 March 21, 2019 8.0% $ 1.75 0.4 (0.2 ) 0.2 December 4, 2019 8.0% $ 1.75 0.9 (0.9 ) — March 1, 2020 8.0% $ 1.75 0.8 (0.8 ) — March 21, 2020 8.0% $ 1.75 0.1 (0.1 ) — Balance at December 31, 2018 $ 4.5 $ (2.5 ) $ 2.0

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Stockholders Equity Note [Abstract]
Stockholders' Equity	(9) Stockholders’ Equity Preferred Stock Issuances Series D Preferred Stock On November 5, 2018, the Company’s Board authorized the establishment of a new series of preferred stock designated as Series D Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock. On March 29, 2019, the Company exchanged all issued and outstanding shares of its Series D Preferred Stock (having an aggregate stated value of $1,160,000) and received $400,000 in cash proceeds in exchange for the issuance of the March 2019 Notes. Please see the discussion under Note 8 above. Common Stock Issuances During the six months ended June 30, 2019 the Company issued 7.9 million shares of the Company’s common stock pursuant to the exercise of Pre-Funded Series D Warrants that were issued in connection with the 2018 Notes discussed in Note 8 above. Warrant Exchange In April 2019, the Company entered into an exchange agreement with an institutional investor with respect to warrants held by such investor (the “February 2018 Warrants”). The February 2018 Warrants were issued to several institutional investors as part of the Company’s February 2018 sale of the Company’s common stock and the issuance of warrants to purchase common shares. Pursuant to the exchange agreement, the Company issued 64,000 shares of the Company’s common stock (the “Exchange Shares”) in exchange for the February 2018 Warrants. The exchange resulted in a loss of approximately $6,000 which is recognized in the statement of operations. Share-Based Compensation The Company’s 2019 Equity Incentive Plan (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. The maximum number of shares reserved for issuance under the Plan is 1,500,000. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair value on the dates of grant. As of June 30, 2019, the Plan had approximately 333,333 shares available for grant. The following is a summary of stock option activity under the Plan for the six months ended June 30, 2019: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2018 — Granted 1,250,000 0.28 Exercised — Cancelled/Forfeited (83,333 ) 0.28 Outstanding at June 30, 2019 1,166,667 $ 0.28 8.8 $ — Exercisable at June 30, 2019 399,998 $ 0.28 9.2 $ — The following weighted average assumptions were used to compute the fair value of stock options granted during the six months ended June 30, 2019: Six months ended June 30, 2019 Dividend yield N/A Expected volatility 147.6 % Weighted average risk-free interest rate 2.6 % Weighted average expected life (in years) 5.5 Weighted average grant date fair value $ 0.259 At June 30, 2019, there was approximately $0.2 million of total unrecognized compensation expense related to non-vested share-based compensation awards under the plans for employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 0.6 years. For the three and six months ended June 30, 2019, the Company recognized share-based compensation expense of approximately $75,000 and $133,000 in the statement of operations, respectively. For the same periods in 2018, the Company recognized share-based compensation income of approximately $140,000 and $121,000 in the statement of operations, respectively. Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Selling, general and administrative $ 58 $ (71 ) $ 106 $ (58 ) Research and development 17 (69 ) 27 (63 ) Total $ 75 $ (140 ) $ 133 $ (121 ) Warrants The following is a summary of warrant activity for the six months ended June 30, 2019: Warrants Exercise Share Weighted Exercise Price Weighted Average Remaining (Years) Outstanding at December 31, 2018 65,685,269 $0.01 - $10.00 $ 0.22 5.75 Exercised (7,898,853 ) 0.01 Exchanged (64,000 ) Outstanding at June 30, 2019 57,722,416 $0.01 - $10.00 $ 0.23 5.24

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	(10) Fair Value Measurements The table below presents the activity within Level 3 of the fair value hierarchy for the six months ended June 30, 2019: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at December 31, 2018 $ 33 Total change in the liability included in earnings (17 ) Reclass from liability to equity (7 ) Balance at June 30, 2019 $ 9 At June 30, 2019, the Company had a total of 125,000 February 2018 Warrants outstanding. As discussed in Part II – Item 1 “Legal Proceedings” and in Note 12 to the Company’s condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q, the February 2018 Warrants were surrendered pursuant to a settlement agreement entered into between the Company and the remaining holders of the February 2018 Warrants on April 18, 2019 and final payment under the settlement was made on July 16, 2019. The fair value of the February 2018 Warrants at June 30, 2019 and December 31, 2018 was determined by using option pricing models with the following assumptions: June 30, December 31, 2019 2018 Expected life (in years) 4.50 1.13 - 5.11 Expected volatility 163.6% 145.7% - 265.3% Risk-free interest rates 1.8% 2.5% - 2.6% The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2019, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820. Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) Level 1 Level 2 Level 3 Total June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 Liabilities Derivative instrument liabilities $ — $ — $ — $ — $ 9 $ 33 $ 9 $ 33 For the periods ended June 30, 2019 and December 31, 2018, there were no transfers in or out of Level 1, 2 or 3 inputs.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Net Loss per Common Share	(11) Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. June 30, (in thousands, except share data) 2019 2018 Net (loss) income - basic $ (13,853 ) $ 527 Adjustment for gain on warrant income — (619 ) Net loss - diluted $ (13,853 ) $ (92 ) Weighted average shares outstanding - basic* 72,069,390 788,512 Weighted average shares outstanding - diluted* 72,069,390 799,430 Net loss per share - basic* $ (0.19 ) $ 0.67 Net loss per share - diluted* $ (0.19 ) $ (0.12 ) * At June 30, 2019, the Company had 53.4 million pre-funded warrants outstanding. The following table provides a reconciliation of the weighted average shares outstanding calculation for the three and six months ended June 30, 2019: (in thousands) Three months ended June 30, 2019 Six months ended June 30, 2019 Weighted average shares issued 17,910,886 18,676,912 Weighted average pre-funded warrants 53,392,478 53,392,478 Weighted average shares outstanding 71,303,364 72,069,390 The following potentially dilutive securities were excluded from the computation of earnings per share as of June 30, 2019 and 2018 because their effects would be anti-dilutive: June 30, 2019 2018 Stock options 1,166,667 — Common stock warrants - equity 4,202,909 — Common stock warrants - liability 125,029 2,116,296 Assumed conversion of convertible notes 335,697 1,116,255 Total 5,830,302 3,232,551

Taxes

Taxes	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Taxes	(12) Taxes As discussed in Note 14 Income Taxes The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Additional information regarding the statutes of limitations can be found in Note 14 Income Taxes

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(13) Commitment and Contingencies As previously reported, on March 26, 2019, the Company commenced an action (the “Action”) in the Commercial Division of the Supreme Court for the State of New York, County of New York, captioned Delcath Systems, Inc., v. Iroquois Capital Investment Group LLC, Iroquois Master Fund Ltd., L1 Capital Global Opportunities Master Fund and First Fire Global Opportunities Fund LLC On May 9, 2018, the Company received a Demand Letter from a vendor for an outstanding balance owed at that time of $2.1 million. The Company has worked with the vendor since that time to establish a payment plan for the balance owed.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	(14) Subsequent Events Debt Issuances On June 6, 2019, the Company entered into an agreement with two institutional investors, pursuant to which the investors agreed to transfer and surrender to the Company for cancellation of warrants to purchase 3.9 million shares of the Company’s common stock (the “Series D Warrants”) and warrants to purchase 53.4 million shares of the Company’s common stock (the “Pre-Funded Series D Warrants”). Under the terms of the Purchase Agreement, the investors agreed to defer the payment of the purchase price for the Series D Warrants and Pre-Funded Series D Warrants and, accordingly, the Company agreed to sell and issue to the investors 8% Senior Secured Promissory Notes in an aggregate principal amount of $2 million in full payment and satisfaction of the purchase price for the Series D Warrants and Pre-Funded Series D Warrants. This agreement was effective upon the closing of the Company’s Private Placement discussed below. Equity Financing On July 11, 2019, the Company and certain accredited investors entered into a securities purchase agreement pursuant to which the Company sold to investors an aggregate of 20,000 shares of Series E convertible preferred stock, par value $0.01 per share (the “Series E Preferred Stock”) $ million

General (Policies)

General (Policies)	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Liquidity and Operating Matters	Liquidity and Operating Matters The accompanying interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and expects to continue incurring losses for the next several years. These losses, among other factors, raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.
Basis of Presentation	Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended June 30, 2019 and 2018; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220). ASU 2018-02 allows a company to elect a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. ASU 2018-02 is effective for periods beginning after December 15, 2018. Upon adoption of ASU 2018-02, the Company did not elect to reclassify the tax effects of the Tax Cuts and Jobs Act from accumulated other comprehensive income to retained earnings, as the stranded tax effects were insignificant. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) effective January 1, 2019, electing the practical expedients and applying the transition provisions as of the effective date. Reporting periods beginning on or after January 1, 2019 are presented under Topic 842, while prior period amounts, as reported under previous GAAP, were not adjusted. The adoption of Topic 842 on January 1, 2019 did not have a significant impact on the Company’s consolidated results of operations or cash flows.

Restricted Cash (Tables)

Restricted Cash (Tables)	6 Months Ended
	Jun. 30, 2019
Restricted Cash [Abstract]
Schedule of Cash, Cash Equivalents, and Restricted Cash	Cash, cash equivalents, and r estricted cash balances were as follows: June 30, December 31, (in thousands) 2019 2018 Cash and cash equivalents $ 352 $ 2,516 Letters of credit 1,012 1,012 Security for credit cards 50 50 Total cash, cash equivalents and restricted cash shown in the statements of cash flows $ 1,414 $ 3,578

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consist of the following: June 30, December 31, (in thousands) 2019 2018 Raw materials $ 307 $ 358 Work-in-process 380 500 Total inventories $ 687 $ 858

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: June 30, December 31, (in thousands) 2019 2018 Insurance premiums $ 175 $ 140 Sublease income 127 — Financing costs 80 — Security deposit 50 51 Income tax and VAT receivable 31 579 Other 1 201 128 Total prepaid expenses and other current assets $ 664 $ 898 1 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at June 30, 2019 and December 31, 2018.

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	6 Months Ended
	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Components of property, plant and equipment	Property, plant, and equipment consist of the following: June 30, December 31, Estimated (in thousands) 2019 2018 Useful Life Buildings and land $ 589 $ 589 30 years - Buildings Enterprise hardware and software 1,742 1,742 3 years Leaseholds 1,700 1,701 Lesser of lease term or estimated useful life Equipment 1,003 1,002 7 years Furniture 198 198 5 years Property, plant and equipment, gross 5,232 5,232 Accumulated depreciation (4,427 ) (4,307 ) Property, plant and equipment, net $ 805 $ 925

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Schedule of accrued expenses	Accrued expenses consist of the following: June 30, December 31, (in thousands) 2019 2018 Compensation, excluding taxes $ 3,469 $ 1,785 Clinical trial expenses 4,289 4,530 Interest payable 731 402 Other 1 630 1,247 Total accrued expenses $ 9,119 $ 7,964 1 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at June 30, 2019 and December 31, 2018.

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Summary of Operating and Financing Leases	The following table summarizes the Company’s operating and financing leases as of and for the six months ended June 30, 2019: (in thousands) U.S. Ireland Total Lease cost Operating lease cost $ 475 $ 112 $ 587 Financing lease cost 19 — 19 Sublease income (215 ) (93 ) (308 ) Total $ 279 $ 19 298 Other information Operating cash flows out from operating leases (516 ) (112 ) (628 ) Operating cash flows in from operating leases 215 93 308 Operating cash flows from financing leases (24 ) — (24 ) Right-of-use assets exchanged for new operating lease liabilities 874 — 874 Weighted average remaining lease term 1.7 2.1 Weighted average discount rate - operating leases 8 % 8 %
Schedule of Maturity of Operating Leases Excluding Short-Term Leases	Maturities of the Company’s operating leases, excluding short-term leases, are as follows: (in thousands) U.S. Ireland Total Six months ended December 31, 2019 $ 472 $ 107 $ 579 Year ended December 31, 2020 936 213 1,149 Year ended December 31, 2021 190 124 314 Total 1,598 444 2,042 Less present value discount (108 ) (36 ) (144 ) Operating lease liabilities included in the condensed consolidated balance sheets at June 30, 2019 $ 1,490 $ 408 $ 1,898

Outstanding Debt (Tables)

Outstanding Debt (Tables)	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Summary of Various Notes Issued	The following tables provide a summary of the various notes issued at June 30, 2019 and December 31, 2018: (in millions) Conversion price Current interest rate Principal Unamortized discount Carrying value Short term convertible notes payable 8.0% 2018 Notes $ 1.75 18 % $ 0.6 (0.1 ) $ 0.5 Short term notes payable 8.0% 2018 Notes — 18 % 5.0 (0.1 ) 4.9 8.0% 2019 Notes — 8 % 4.9 — 4.9 9.9 (0.1 ) 9.8 Balance at June 30, 2019 $ 10.5 $ (0.2 ) $ 10.3 (in millions) Interest rate Conversion price Principal Unamortized discount Carrying value December 4, 2018 8.0% $ 1.75 $ 1.7 $ — $ 1.7 March 1, 2019 8.0% $ 1.75 0.6 (0.5 ) 0.1 March 21, 2019 8.0% $ 1.75 0.4 (0.2 ) 0.2 December 4, 2019 8.0% $ 1.75 0.9 (0.9 ) — March 1, 2020 8.0% $ 1.75 0.8 (0.8 ) — March 21, 2020 8.0% $ 1.75 0.1 (0.1 ) — Balance at December 31, 2018 $ 4.5 $ (2.5 ) $ 2.0

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2019
Stockholders Equity Note [Abstract]
Summary of Stock Option Activity	The following is a summary of stock option activity under the Plan for the six months ended June 30, 2019: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2018 — Granted 1,250,000 0.28 Exercised — Cancelled/Forfeited (83,333 ) 0.28 Outstanding at June 30, 2019 1,166,667 $ 0.28 8.8 $ — Exercisable at June 30, 2019 399,998 $ 0.28 9.2 $ —
Summary of Weighted Average Assumptions Used to Compute Fair Value	The following weighted average assumptions were used to compute the fair value of stock options granted during the six months ended June 30, 2019: Six months ended June 30, 2019 Dividend yield N/A Expected volatility 147.6 % Weighted average risk-free interest rate 2.6 % Weighted average expected life (in years) 5.5 Weighted average grant date fair value $ 0.259
Summary of Recognized Share-based Compensation Cost	Three months ended June 30, Six months ended June 30, (in thousands) 2019 2018 2019 2018 Selling, general and administrative $ 58 $ (71 ) $ 106 $ (58 ) Research and development 17 (69 ) 27 (63 ) Total $ 75 $ (140 ) $ 133 $ (121 )
Summary of Warrant Activity	The following is a summary of warrant activity for the six months ended June 30, 2019: Warrants Exercise Share Weighted Exercise Price Weighted Average Remaining (Years) Outstanding at December 31, 2018 65,685,269 $0.01 - $10.00 $ 0.22 5.75 Exercised (7,898,853 ) 0.01 Exchanged (64,000 ) Outstanding at June 30, 2019 57,722,416 $0.01 - $10.00 $ 0.23 5.24

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair value measurements using significant unobservable inputs	The table below presents the activity within Level 3 of the fair value hierarchy for the six months ended June 30, 2019 Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at December 31, 2018 $ 33 Total change in the liability included in earnings (17 ) Reclass from liability to equity (7 ) Balance at June 30, 2019 $ 9
Schedule of fair value of the warrants	The fair value of the February 2018 Warrants at June 30, 2019 and December 31, 2018 was determined by using option pricing models with the following assumptions: June 30, December 31, 2019 2018 Expected life (in years) 4.50 1.13 - 5.11 Expected volatility 163.6% 145.7% - 265.3% Risk-free interest rates 1.8% 2.5% - 2.6%
Assets and liabilities measured at fair value on a recurring basis	The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2019, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820. Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) Level 1 Level 2 Level 3 Total June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018 Liabilities Derivative instrument liabilities $ — $ — $ — $ — $ 9 $ 33 $ 9 $ 33

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Calculation of net loss and number of shares used to compute basic and diluted earnings per share	Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. June 30, (in thousands, except share data) 2019 2018 Net (loss) income - basic $ (13,853 ) $ 527 Adjustment for gain on warrant income — (619 ) Net loss - diluted $ (13,853 ) $ (92 ) Weighted average shares outstanding - basic* 72,069,390 788,512 Weighted average shares outstanding - diluted* 72,069,390 799,430 Net loss per share - basic* $ (0.19 ) $ 0.67 Net loss per share - diluted* $ (0.19 ) $ (0.12 ) *
Summary of Reconciliation of Weighted Average Shares Outstanding Calculation	The following table provides a reconciliation of the weighted average shares outstanding calculation for the three and six months ended June 30, 2019: (in thousands) Three months ended June 30, 2019 Six months ended June 30, 2019 Weighted average shares issued 17,910,886 18,676,912 Weighted average pre-funded warrants 53,392,478 53,392,478 Weighted average shares outstanding 71,303,364 72,069,390
Anti-dilutive securities excluded from the computation of earnings per share	The following potentially dilutive securities were excluded from the computation of earnings per share as of June 30, 2019 and 2018 because their effects would be anti-dilutive: June 30, 2019 2018 Stock options 1,166,667 — Common stock warrants - equity 4,202,909 — Common stock warrants - liability 125,029 2,116,296 Assumed conversion of convertible notes 335,697 1,116,255 Total 5,830,302 3,232,551

Restricted Cash - Schedule of C

Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Restricted Cash [Abstract]
Cash and cash equivalents	$ 352	$ 2,516
Letters of credit	1,012	1,012
Security for credit cards	50	50
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$ 1,414	$ 3,578	$ 2,345	$ 5,324

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 307	$ 358
Work-in-process	380	500
Total inventories	$ 687	$ 858

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 175	$ 140
Sublease income	127
Financing costs	80
Security deposit	50	51
Income tax and VAT receivable	31	579
Other	201	128
Total prepaid expenses and other current assets	$ 664	$ 898

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets - Additional Information (Details)	Jun. 30, 2019	Dec. 31, 2018
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%

Property, Plant, and Equipmen_2

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 5,232	$ 5,232
Accumulated depreciation	(4,427)	(4,307)
Property, plant and equipment, net	805	925
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	589	589
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,742	1,742
Property, plant and equipment, estimated useful life	3 years
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,700	1,701
Property, plant and equipment, estimated useful life	Lesser of lease term or estimated useful life
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,003	1,002
Property, plant and equipment, estimated useful life	7 years
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 198	$ 198
Property, plant and equipment, estimated useful life	5 years
Buildings [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, estimated useful life	30 years

Property, Plant, and Equipmen_3

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Depreciation expense	$ 100	$ 100	$ 122	$ 236

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Compensation, excluding taxes	$ 3,469	$ 1,785
Clinical trial expenses	4,289	4,530
Interest payable	731	402
Other	630	1,247
Total accrued expenses	$ 9,119	$ 7,964

Accrued Expenses - Schedule o_2

Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details)	Jun. 30, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%

Leases - Additional Information

Leases - Additional Information (Details)	Jun. 30, 2019
Leases [Abstract]
Lease term	12 months

Leases - Summary of Operating a

Leases - Summary of Operating and Financing Leases (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Lease cost
Operating lease cost	$ 587
Financing lease cost	19
Sublease income	(308)
Total	298
Other information
Operating cash flows out from operating leases	(628)
Operating cash flows in from operating leases	308
Operating cash flows from financing leases	(24)
Right-of-use assets exchanged for new operating lease liabilities	874
U.S. [Member]
Lease cost
Operating lease cost	475
Financing lease cost	19
Sublease income	(215)
Total	279
Other information
Operating cash flows out from operating leases	(516)
Operating cash flows in from operating leases	215
Operating cash flows from financing leases	(24)
Right-of-use assets exchanged for new operating lease liabilities	$ 874
Weighted average remaining lease term	1 year 8 months 12 days
Weighted average discount rate - operating leases	8.00%
Ireland [Member]
Lease cost
Operating lease cost	$ 112
Sublease income	(93)
Total	19
Other information
Operating cash flows out from operating leases	(112)
Operating cash flows in from operating leases	$ 93
Weighted average remaining lease term	2 years 1 month 6 days
Weighted average discount rate - operating leases	8.00%

Leases - Schedule of Maturity o

Leases - Schedule of Maturity of Operating Leases Excluding Short-Term Leases (Details) $ in Thousands	Jun. 30, 2019USD ($)
Lessee Lease Description [Line Items]
Six months ended December 31, 2019	$ 579
Year ended December 31, 2020	1,149
Year ended December 31, 2021	314
Total	2,042
Less present value discount	(144)
Operating lease liabilities included in the condensed consolidated balance sheets at June 30, 2019	1,898
U.S. [Member]
Lessee Lease Description [Line Items]
Six months ended December 31, 2019	472
Year ended December 31, 2020	936
Year ended December 31, 2021	190
Total	1,598
Less present value discount	(108)
Operating lease liabilities included in the condensed consolidated balance sheets at June 30, 2019	1,490
Ireland [Member]
Lessee Lease Description [Line Items]
Six months ended December 31, 2019	107
Year ended December 31, 2020	213
Year ended December 31, 2021	124
Total	444
Less present value discount	(36)
Operating lease liabilities included in the condensed consolidated balance sheets at June 30, 2019	$ 408

Outstanding Debt - Additional I

Outstanding Debt - Additional Information (Details) - USD ($)	Mar. 29, 2019	May 23, 2019	Jun. 30, 2019	Jun. 06, 2019	Apr. 30, 2019	Dec. 31, 2018	Sep. 21, 2018
Debt Instrument [Line Items]
Interest rate				8.00%
Debt instrument, principal face amount			$ 10,500,000	$ 2,000,000		$ 4,500,000
Short Term Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount			$ 9,900,000
Series D Preferred Shares [Member]
Debt Instrument [Line Items]
Interest rate	8.00%
Preferred stock, stated value	$ 1,160,000
Proceeds from exchange of senior secured promissory note	400,000
Issuance of senior secured promissory note in exchange of preferred stock	$ 1,560,000
Maturity date	Apr. 1, 2020
Senior Secured Notes
Debt Instrument [Line Items]
Interest rate		8.00%
Debt instrument, principal face amount		$ 3,300,000
Maturity period		6 months
Senior Secured Convertible Notes
Debt Instrument [Line Items]
Interest rate							8.00%
Debt instrument, principal face amount							$ 9,400,000
Debt instrument maturity start date			Dec. 31, 2018
Debt instrument maturity end date			Mar. 31, 2021
8.0% 2018 Notes [Member] | Short Term Notes Payable [Member]
Debt Instrument [Line Items]
Interest rate			18.00%
Debt instrument, principal face amount			$ 5,000,000
Debt instrument, notice of default description			Company received notices of default from the investors in the 2018 Notes which resulted in a 25%, or $1.1 million, increase in principal and an increase in the interest rates from 8% to 18%.
Debt instrument, default amount percentage					25.00%
Debt instrument, default amount					$ 1,100,000
Increase in interest rate on notes in event of default					18.00%

Outstanding Debt - Summary of V

Outstanding Debt - Summary of Various Notes Issued (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2019	Jun. 06, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Interest rate		8.00%
Principal	$ 10.5	$ 2	$ 4.5
Unamortized discount	(0.2)		(2.5)
Carrying value	$ 10.3		$ 2
December 4, 2018 [Member]
Debt Instrument [Line Items]
Maturity date	Dec. 4, 2018
Interest rate			8.00%
Conversion price			$ 1.75
Principal			$ 1.7
Carrying value			$ 1.7
March 1, 2019 [Member]
Debt Instrument [Line Items]
Maturity date	Mar. 1, 2019
Interest rate			8.00%
Conversion price			$ 1.75
Principal			$ 0.6
Unamortized discount			(0.5)
Carrying value			$ 0.1
March 21, 2019 [Member]
Debt Instrument [Line Items]
Maturity date	Mar. 21, 2019
Interest rate			8.00%
Conversion price			$ 1.75
Principal			$ 0.4
Unamortized discount			(0.2)
Carrying value			$ 0.2
December 4, 2019 [Member]
Debt Instrument [Line Items]
Maturity date	Dec. 4, 2019
Interest rate			8.00%
Conversion price			$ 1.75
Principal			$ 0.9
Unamortized discount			$ (0.9)
March 1, 2020 [Member]
Debt Instrument [Line Items]
Maturity date	Mar. 1, 2020
Interest rate			8.00%
Conversion price			$ 1.75
Principal			$ 0.8
Unamortized discount			$ (0.8)
March 21, 2020 [Member]
Debt Instrument [Line Items]
Maturity date	Mar. 21, 2020
Interest rate			8.00%
Conversion price			$ 1.75
Principal			$ 0.1
Unamortized discount			$ (0.1)
Short Term Convertible Notes Payable [Member] | 8.0% 2018 Notes [Member]
Debt Instrument [Line Items]
Interest rate	18.00%
Conversion price	$ 1.75
Principal	$ 0.6
Unamortized discount	(0.1)
Carrying value	0.5
Short Term Notes Payable [Member]
Debt Instrument [Line Items]
Principal	9.9
Unamortized discount	(0.1)
Carrying value	$ 9.8
Short Term Notes Payable [Member] | 8.0% 2018 Notes [Member]
Debt Instrument [Line Items]
Interest rate	18.00%
Principal	$ 5
Unamortized discount	(0.1)
Carrying value	$ 4.9
Short Term Notes Payable [Member] | 8.0% 2019 Notes [Member]
Debt Instrument [Line Items]
Interest rate	8.00%
Principal	$ 4.9
Carrying value	$ 4.9

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details) - USD ($)	Mar. 29, 2019	Jun. 30, 2019	Dec. 31, 2018	Nov. 05, 2018
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.01	$ 0.01
Preferred stock, aggregate stated value		$ 0	$ 0
Series D Preferred Shares [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share)				$ 0.01
Preferred stock, aggregate stated value	$ 1,160,000
Proceeds from exchange of senior secured promissory note	$ 400,000

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock Issuances - Additional Information (Details) shares in Millions	6 Months Ended
	Jun. 30, 2019shares
Pre-Funded Series D Warrants [Member]
Stockholders Equity Note [Line Items]
Exercise of pre-funded Series D Warrants (in shares)	7.9

Stockholders' Equity - Warrant

Stockholders' Equity - Warrant Exchange - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stockholders Equity Note [Line Items]
Loss in exchange of common stock for warrants		$ 6,000	$ 2,826,000	$ 6,000	$ 2,826,000
Exchange Agreement [Member]
Stockholders Equity Note [Line Items]
Shares of common stock issued for exchange warrants	64,000
Loss in exchange of common stock for warrants	$ 6,000

Stockholders' Equity - Share-Ba

Stockholders' Equity - Share-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to non-vested share-based compensation awards	$ 200,000		$ 200,000
Cost expected to be recognized over weighted average period			7 months 6 days
Share-based compensation (Income) expense	$ 75,000	$ (140,000)	$ 133,000	$ (121,000)
2019 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for grant	333,333		333,333
2019 Equity Incentive Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance	1,500,000		1,500,000
2019 Equity Incentive Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, exercise price of common stock granted as percentage of fair value on the date of grant			100.00%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Stockholders Equity Note [Abstract]
Number of Shares, Granted | shares	1,250,000
Number of Shares, Cancelled/Forfeited | shares	(83,333)
Number of Shares, Outstanding | shares	1,166,667
Number of Shares, Exercisable | shares	399,998
Weighted Average Exercise Price, Granted | $ / shares	$ 0.28
Weighted Average Exercise Price, Cancelled/Forfeited | $ / shares	0.28
Weighted Average Exercise Price, Outstanding | $ / shares	0.28
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.28
Weighted Average Remaining Contractual Term (Years), Outstanding	8 years 9 months 18 days
Weighted Average Remaining Contractual Term (Years), Exercisable	9 years 2 months 12 days

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Weighted Average Assumptions Used to Compute Fair Value (Details) - Stock Options [Member]	6 Months Ended
	Jun. 30, 2019$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	147.60%
Weighted average risk-free interest rate	2.60%
Weighted average expected life (in years)	5 years 6 months
Weighted average grant date fair value	$ 0.259

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	$ 75,000	$ (140,000)	$ 133,000	$ (121,000)
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	58,000	(71,000)	106,000	(58,000)
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	$ 17,000	$ (69,000)	$ 27,000	$ (63,000)

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Warrant Activity (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2019$ / sharesshares	Dec. 31, 2018$ / sharesshares
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares) | shares	65,685,269
Exercised (in shares) | shares	(7,898,853)
Exchanged (in shares) | shares	(64,000)
Outstanding, end of period (in shares) | shares	57,722,416	65,685,269
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 0.23	$ 0.22
Warrants, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	0.22
Exercised (in dollars per share)	0.01
Outstanding, end of period (in dollars per share)	$ 0.23	$ 0.22
Weighted average remaining life	5 years 2 months 26 days	5 years 9 months
Minimum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 0.01	$ 0.01
Maximum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 10	$ 10

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 33
Total change in the liability included in earnings	(17)
Reclass from liability to equity	(7)
Ending balance	$ 9

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - shares	Jun. 30, 2019	Dec. 31, 2018
Class Of Warrant Or Right [Line Items]
Warrants outstanding	57,722,416	65,685,269
Febuary 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants outstanding	125,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Warrants (Details)	Jun. 30, 2019	Dec. 31, 2018
Contractual Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants expiration period	4 years 6 months
Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants measurement input	1.636
Risk-free Interest Rates [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants measurement input	0.018
Minimum [Member] | Contractual Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants expiration period		1 year 1 month 17 days
Minimum [Member] | Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants measurement input		1.457
Minimum [Member] | Risk-free Interest Rates [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants measurement input		0.025
Maximum [Member] | Contractual Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants expiration period		5 years 1 month 9 days
Maximum [Member] | Expected Volatility [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants measurement input		2.653
Maximum [Member] | Risk-free Interest Rates [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants measurement input		0.026

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Derivative Instruments Liabilities [Member] - Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Liabilities [Abstract]
Total Liabilities	$ 9	$ 33
Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	$ 9	$ 33

Net Loss per Common Share - Cal

Net Loss per Common Share - Calculation of Net Loss and Number of Shares Used to Compute Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended				6 Months Ended
		Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Net (loss) income - basic		$ (5,959)	$ (7,894)	$ (6,658)	$ 7,185	$ (13,853)	$ 527
Adjustment for gain on warrant income							(619)
Net loss - diluted						$ (13,853)	$ (92)
Weighted average shares outstanding - basic	[1]	71,303,364		916,706		72,069,390	788,512
Weighted average shares outstanding - diluted	[1]	71,303,364		916,706		72,069,390	799,430
Net loss per share - basic	[1]	$ (0.08)		$ (7.26)		$ (0.19)	$ 0.67
Net loss per share - diluted*	[1]	$ (0.08)		$ (7.26)		$ (0.19)	$ (0.12)
[1]	reflects a one-for-five hundred (1:500) reverse stock split effected on May 2, 2018.

Net Loss per Common Share - C_2

Net Loss per Common Share - Calculation of Net Loss and Number of Shares Used to Compute Basic and Diluted Earnings per Share (Parenthetical) (Details)	May 02, 2018
Earnings Per Share [Abstract]
Reverse stock split	1:500
Reverse stock split ratio	0.002

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Details) shares in Millions	6 Months Ended
	Jun. 30, 2019shares
Earnings Per Share [Abstract]
Pre-funded penny warrants outstanding	53.4

Net Loss per Common Share - Sum

Net Loss per Common Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) - shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Earnings Per Share [Abstract]
Weighted average shares issued	17,910,886	18,676,912
Weighted average pre-funded warrants	53,392,478	53,392,478
Weighted average shares outstanding	71,303,364	72,069,390

Net Loss per Common Share - Ant

Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,830,302	3,232,551
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,166,667
Common Stock Warrants - Equity [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,202,909
Common Stock Warrants - Liability [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	125,029	2,116,296
Assumed Conversion of Convertible Notes [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	335,697	1,116,255

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Details) - USD ($)	Jul. 17, 2019	Apr. 18, 2019	May 09, 2018
Loss Contingencies [Line Items]
Outstanding balance to vendor			$ 2,100,000
Settlement Agreement [Member]
Loss Contingencies [Line Items]
Litigation settlement agreement date		April 18, 2019
Litigation settlement, agreed to pay amount to defendants		$ 400,000
Settlement Agreement [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Payments for defendants settlement	$ 440,000
Settlement Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Settlement fees		$ 50,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Jul. 11, 2019	Jun. 30, 2019	Jun. 06, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Debt instrument, principal face amount		$ 10.5	$ 2	$ 4.5
Interest rate on promissory note			8.00%
Preferred stock, par value (in dollars per share)		$ 0.01		$ 0.01
Warrant exercise price		$ 0.23		$ 0.22
Roth Capital Partners, LLC [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payments to private placement agent	$ 0.6
Series E Preferred Stock [Member] | Private Placement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from private placement, gross	20
Series E Preferred Stock [Member] | Private Placement [Member] | Roth Capital Partners, LLC [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payments to private placement agent	$ 1.4
Series E Preferred Stock [Member] | Private Placement [Member] | Securities Purchase Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued	20,000
Preferred stock, par value (in dollars per share)	$ 0.01
Shares issued, price per share	1,000
Series D Warrants [Member]
Subsequent Event [Line Items]
Number of common shares issuable on cancellation of warrants			3,900,000
Pre-Funded Series D Warrants [Member]
Subsequent Event [Line Items]
Number of common shares issuable on cancellation of warrants			53,400,000
2019 Warrants [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Warrant exercise price	$ 0.06
Warrant exercisable term	5 years